Author

R. Brian Mitchell

Observed names: R B Mitchell, R Brian Mitchell, R MITCHELL, R. Mitchell, R.Brian Mitchell, Reed Brian Mitchell

Observed institutions: Greater Baltimore Medical Center, Loyola University Medical Center, St. Jude Children's Research Hospital, American Society of Clinical Oncology, Memorial Sloan Kettering Cancer Center, Johns Hopkins University, Virginia Commonwealth University, Washington University in St. Louis, Johns Hopkins Medicine, Moffitt Cancer Center, University of Mississippi, University of Chicago, Virginia Cancer Institute, Tennessee Oncology, Virginia Commonwealth University Medical Center

OpenAlex ID: A5113624102

American Society of Clinical Oncology 2008 Clinical Practice Guideline Update: Use of Chemotherapy and Radiation Therapy Protectants

2008 · Martee L. Hensley, Karen L. Hagerty, et al. · Journal of Clinical Oncology · 537

American Society of Clinical Oncology Clinical Practice Guidelinesfor the Use of Chemotherapy and Radiotherapy Protectants

1999 · Martee L. Hensley, LynnM. Schuchter, et al. · Journal of Clinical Oncology · 330

Effect of O6-benzylguanine analogues on sensitivity of human tumor cells to the cytotoxic effects of alkylating agents.

1991 · M E Dolan, R B Mitchell, et al. · PubMed · 222

Randomized, Double-Blind, Placebo-Controlled, Phase II Trial of Sorafenib and Erlotinib or Erlotinib Alone in Previously Treated Advanced Non–Small-Cell Lung Cancer

2011 · David R. Spigel, Howard A. Burris, et al. · Journal of Clinical Oncology · 159

Syndrome of Idiopathic Hyperammonemia after High-Dose Chemotherapy: Review of Nine Cases

1988 · R MITCHELL, J WAGNER, et al. · The American Journal of Medicine · 108

Effect of O6-benzylguanine on the sensitivity of human tumor xenografts to 1,3-bis(2-chloroethyl)-1-nitrosourea and on DNA interstrand cross-link formation.

1992 · R B Mitchell, R C Moschel, et al. · PubMed · 103

Modulation of Mammalian O6-Alkylguanine-DNA Alkyltransferase in vivo by O6-Benzylguanine and its Effect on the Sensitivity of a Human Glioma Tumor to l-(2-chloroethyl)-3-(4-methylcyclohexyl)-l-nitrosourea

1990 · M. Eileen Dolan, Linda Stine, et al. · Cancer Communications · 94

Effect of temozolomide and dacarbazine on O6-alkylguanine-DNA alkyltransferase activity and sensitivity of human tumor cells and xenografts to 1,3-bis(2-chloroethyl)-1-nitrosourea

1993 · R. Brian Mitchell, M. Eileen Dolan · Cancer Chemotherapy and Pharmacology · 46

Differentiation of normal marrow and HL60 cells induced by antithymocyte globulin.

1985 · R F Hunter, N G Mold, et al. · Proceedings of the National Academy of Sciences · 35

PDF

Real-world performance of blood-based proteomic profiling in first-line immunotherapy treatment in advanced stage non-small cell lung cancer

2021 · Patricia Rich, R Brian Mitchell, et al. · Journal for ImmunoTherapy of Cancer · 22

PDF

Experimental Rationale for Continuous Infusion Chemotherapy

1991 · R. Brian Mitchell, Mark J. Ratain, et al. · Medical radiology · 17

Phase II trial of preoperative pemetrexed plus carboplatin in patients with stage IB-III nonsquamous non-small cell lung cancer (NSCLC)

2018 · John D. Hainsworth, David M. Waterhouse, et al. · Lung Cancer · 11

Sequential therapy with dacarbazine and carmustine: a phase I study

1994 · R. Brian Mitchell, M. Eileen Dolan, et al. · Cancer Chemotherapy and Pharmacology · 9

Carboplatin and Paclitaxel for Previously Treated Patients with Non-small-cell Lung Cancer

1998 · Veronica Roa, Anita Conner, et al. · Cancer Investigation · 7

Real-world performance of blood-based host immune profiling in first-line immunotherapy treatment in advanced-stage non-small cell lung cancer.

2020 · R. Brian Mitchell, Patricia Rich, et al. · Journal of Clinical Oncology · 1

Abstract LB-77: A randomized double-blind placebo-controlled phase II trial of sorafenib and erlotinib or erlotinib alone in previously treated advanced non-small cell lung cancer: Correlative analyses

2010 · David R. Spigel, Howard A. Burris, et al. · Cancer Research · 1

P24.01 Turnaround Time and Variant Prevalence of a Blood-based KRAS Test in Patients With NSCLC

2021 · E. Santos, P. Rich, et al. · Journal of Thoracic Oncology

Abstract 662: Longitudinal blood-based proteomic testing in advanced non-small cell lung cancer

2021 · Eric Schaefer, R. Brian Mitchell, et al. · Cancer Research

FP07.17 The Impact of Blood Based Host Immune Profile to Identify Aggressive Early Stage NSCLC

2021 · E. Schaefer, P. Walker, et al. · Journal of Thoracic Oncology

PDF

MA08.03 Immunotherapy Alone or with Chemotherapy in Advanced NSCLC? Utility of Clinical Factors and Blood-Based Host Immune Profiling.

2021 · W. Akerley, N. Nagajothi, et al. · Journal of Thoracic Oncology

PDF

Phase II trial of preoperative carboplatin (carbo)/pemetrexed (pem) in patients (pts) with select stage IB-IIIA nonsquamous non-small cell lung cancer (NS-NSCLC).

2014 · David Michael Waterhouse, John D. Hainsworth, et al. · Journal of Clinical Oncology

A mechanism for trauma induced muscle wasting and immune dysfunction

2002 · Sundararajan V. Madihally, M. M. Toner, et al. · 34th COSPAR Scientific Assembly

Works count: 22

Citation count: 1,702

H-index: 11

I10-index: 12